Sequoia Financial Advisors LLC bought a new stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 5,289 shares of the company's stock, valued at approximately $282,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Global Retirement Partners LLC raised its position in shares of Doximity by 468.1% during the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock valued at $29,000 after acquiring an additional 440 shares during the last quarter. UMB Bank n.a. increased its position in shares of Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after buying an additional 235 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Doximity by 49.4% in the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after buying an additional 250 shares in the last quarter. Morse Asset Management Inc bought a new stake in shares of Doximity in the 3rd quarter valued at $46,000. Finally, IFP Advisors Inc increased its position in shares of Doximity by 344.1% in the 4th quarter. IFP Advisors Inc now owns 1,328 shares of the company's stock valued at $71,000 after buying an additional 1,029 shares in the last quarter. Institutional investors own 87.19% of the company's stock.
Insider Activity at Doximity
In related news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 37.40% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
DOCS has been the subject of a number of recent analyst reports. Raymond James restated an "outperform" rating and issued a $83.00 price objective (up previously from $65.00) on shares of Doximity in a research report on Friday, February 7th. KeyCorp lowered their target price on Doximity from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Leerink Partners upgraded Doximity from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $60.00 to $90.00 in a report on Friday, February 7th. Mizuho increased their target price on Doximity from $55.00 to $65.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Stephens initiated coverage on Doximity in a report on Friday, December 20th. They set an "equal weight" rating and a $55.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $64.22.
View Our Latest Stock Analysis on Doximity
Doximity Stock Performance
NASDAQ:DOCS traded up $0.24 during mid-day trading on Friday, hitting $63.01. The stock had a trading volume of 4,032,344 shares, compared to its average volume of 1,883,448. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The stock has a market cap of $11.76 billion, a price-to-earnings ratio of 63.01, a PEG ratio of 4.10 and a beta of 1.34. The company's 50 day simple moving average is $64.42 and its 200 day simple moving average is $53.51.
About Doximity
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Read More
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
